A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder.
OBJECTIVE
Regular aerobic exercise (running) has been shown to be superior to a pill placebo in the treatment of panic disorder. Combined drug and exercise treatment has not been investigated in randomized controlled studies to date.


METHODS
This is a randomized, 10-week, controlled, parallel group, pilot study. A total of 75 outpatients with panic disorder with or without agoraphobia (DSM-IV and ICD-10) received either (1) exercise plus paroxetine 40 mg/day (n=21), (2) relaxation plus paroxetine (n=17), (3) exercise plus pill placebo (n=20), or (4) relaxation plus pill placebo (n=17). Changes in the Panic and Agoraphobia Scale (P&A), and the Clinical Global Impression Scale (CGI) underwent repeated measure analysis.


RESULTS
Effects sizes were large for all groups (d=1.53-3.87), however not significantly different. Paroxetine-treated patients were significantly more improved than placebo-treated patients. On the CGI, patients in the exercise groups (plus paroxetine or placebo) had a trend toward better improvement compared to relaxation (P=0.06). Response and remission rates were higher in the paroxetine compared to pill placebo groups.


CONCLUSIONS
While paroxetine was superior to placebo, aerobic exercise did not differ from relaxation training in most efficacy measures.
Wedekind
Dirk
D
Department of Psychiatry and Psychotherapy, University of Goettingen, Goettingen, Germany. dwedeki1@gwdg.de
Broocks
Andreas
A
Weiss
Nina
N
Engel
Kirsten
K
Neubert
Karin
K
Bandelow
Borwin
B
D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D003131:Combined Modality Therapy; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D017374:Paroxetine / Q000627:therapeutic use*; D010865:Pilot Projects; D012064:Relaxation Therapy; D012420:Running / Q000523:psychology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors